In this article, we will discuss Durvalumab (Warnings-7). So, let’s get started.
In Patients Who did Not Receive Recent Prior Radiation
In patients who received Durvalumab on clinical trials in which radiation therapy was generally not administered immediately prior to initiation of Durvalumab, the incidence of immune-mediated pneumonitis was 2.4% (34/1414), including fatal (<0.1%), and Grade 3-4 (0.4%) adverse reactions. Events resolved in 19 of the 34 patients and resulted in permanent discontinuation in 5 patients. Systemic corticosteroids were required in 19 patients (19/34) with pneumonitis who did not receive chemoradiation prior to initiation of Durvalumab.